EUVIMEDEUVIMED entdecken
Crossref

Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations

Hiroaki Ikushima iD, Kousuke Watanabe iD, Aya Shinozaki-Ushiku, Katsutoshi Oda iD, Hidenori Kage iD

JCO Precision Oncology · 2026-05 · 10 (5)

DOI: 10.1200/po-26-00100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-05. Verfasst von Hiroaki Ikushima und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Purine-Nucleoside Phosphorylase, Cyclin-Dependent Kinase Inhibitor p16, Thoracic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Methylthioadenosine phosphorylase ( MTAP ) deletion represents a promising therapeutic vulnerability through synthetic lethality. However, the clinical and molecular context of MTAP -deleted thoracic tumors, particularly with respect to actionable oncogenic drivers and immune checkpoint inhibitor efficacy, remains incompletely defined across diverse populations. METHODS We analyzed clinicogenomic data from two nationwide cohorts: AACR Project GENIE (United States; n = 11,091 evaluable samples) and Center for Cancer Genomics and Advanced Therapeutics (C-CAT; Japan; n = 4,851). MTAP copy number was assessed in lung, pleural, and thymic tumors. We evaluated histology-specific prevalence, comutational patterns, associations with actionable genomic alterations, tumor mutational burden (TMB), and overall survival (OS) in selected molecular subgroups. RESULTS In lung cancer, MTAP deletion occurred at comparable frequencies between adenocarcinoma and squamous cell carcinoma within each cohort (GENIE: 8.1% v 9.8%; C-CAT: 19.6% v 16.5%) but was rare in small cell lung cancer (GENIE: 1.0%; C-CAT: 1.9%). In thymic tumors, MTAP deletion was observed predominantly in thymic carcinoma and was uncommon in thymoma. MTAP deletion was strongly associated with CDKN2A/B deletions and was rare in their absence. MTAP deletion frequently coexisted with actionable driver alterations, including EGFR mutations, ALK fusions, and ERBB2 alterations. A robust inverse association with RB1 mutations was observed in both cohorts. Although MTAP deletion appeared associated with lower TMB ( P < .01) and shorter OS in EGFR -mutated lung cancer (median 18.5 v 31.4 months, P < .01), these associations were largely attributable to enrichment of oncogenic drivers and concurrent CDKN2A loss, respectively. CONCLUSION MTAP -deleted thoracic tumors exhibit reproducible clinical and molecular features across populations. Our findings support the rational, globally applicable development of MTAP -targeted synthetic lethal strategies in thoracic malignancies, particularly in combination with molecular targeted agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purine-Nucleoside PhosphorylaseCyclin-Dependent Kinase Inhibitor p16Thoracic NeoplasmsHumansJapanFemaleUnited StatesMutationMaleCohort StudiesLung NeoplasmsMiddle AgedAgedGene DeletionEast Asian People

Substanzen

5'-methylthioadenosine phosphorylasePurine-Nucleoside PhosphorylaseCyclin-Dependent Kinase Inhibitor p16CDKN2A protein, human

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Hiroaki Ikushima, Kousuke Watanabe, Katsutoshi Oda, Hidenori Kage

Zitieren

APA

Ikushima, H., Watanabe, K., Shinozaki-Ushiku, A., Oda, K., & Kage, H. (2026). Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations. JCO Precision Oncology, 10(5). https://doi.org/10.1200/po-26-00100

Vancouver

Ikushima H, Watanabe K, Shinozaki-Ushiku A, Oda K, Kage H. Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations. JCO Precision Oncology. 2026;10(5). doi:10.1200/po-26-00100

BibTeX
@article{Ikushima2026,
  author = {Ikushima, Hiroaki and Watanabe, Kousuke and Shinozaki-Ushiku, Aya and Oda, Katsutoshi and Kage, Hidenori},
  title = {Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {5},
  doi = {10.1200/po-26-00100}
}
Kostenlos starten →